oncolyticsbiotech.com - ONCY Income before deduction of interest, taxes and amortization

Brandmark of Oncolytics Biotech, Inc. (ONCY)

Oncolytics Biotech Inc. is developing a viral system to stimulate the immune response against tumors while expanding its network of medical partners. Simultaneously, Oncolytics Biotech Inc. is implementing ESG principles by minimizing hazardous waste and adhering to research ethics. The EBITDA_Co indicator confirms the financial dynamics, where 0.00 represents the current level of the metric. The share price here depends on clinical success rather than economic cycles.

ONCY: Oncolytics Profit before payment of interest, taxes and amortization 11/23/2025 - 11/11/2026

Oncolytics Biotech - analytical breakdowns and key metrics (ONCY)

- market value and analyst target forecast:
Market Price Oncolytics Biotech, Inc.|ONCY - Consensus Target
- issuer market value details:
Market Value Oncolytics Biotech|ONCY - Total Company Value
- book capitalization information:
Share Book Value Oncolytics Biotech|ONCY - Company Book Value|Market Value to Book Value Ratio oncolyticsbiotech.com|ONCY - Company Total Assets
- debt level and financial liquidity data:
Total Debt to Capital Oncolytics Biotech Inc.|ONCY - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Oncolytics Biotech, Inc.|ONCY - Company Aggregate Debts|Debts to Book Capitalization Ratio Oncolytics Biotech|ONCY - Company Long-Term Debt|Short-Term Debt Oncolytics Biotech|Intermediate Coverage Ratio oncolyticsbiotech.com
- earnings and valuation multiples information:
ONCY - Company Net Income|Future Profit Oncolytics Biotech Inc.|ONCY - Price to Earnings Ratio|Market Cap to Projected Earnings Oncolytics Biotech, Inc.|ONCY - Price/Earnings to Growth Ratio|Company Value to EBITDA Oncolytics Biotech|ONCY - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Oncolytics Biotech|ONCY - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months oncolyticsbiotech.com|ONCY - Earnings per share growth in current year|Expected net earnings per share growth next year Oncolytics Biotech Inc.
Summary company analytics:Oncolytics Biotech Inc., ONCY
Original product of oncolyticsbiotech.com

The stability of Oncolytics Biotech Inc. (ONCY) depends on its ability to generate cash flow amidst fierce competition for partnerships with pharma behemoths. This metric measures the daily inflow of operating funds, neutralizing the quarterly reporting lag; therefore, a decline in operating earnings momentum signals a loss of liquidity and asset market value even before official publications.

Competitors of Oncolytics Biotech Inc. (ONCY)

Geron Bio (GERN) - Profit before interest, taxes and amortization|NBTX: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization BCYC (bicycletherapeutics.com)|CytomX Therapeutics, Inc. (CTMX) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization CATX (Perspective Therapeutics, Inc.)|Profit before payment of interest, taxes and amortization Genelux Corp.|Profit before payment of interest, taxes and amortization MOLN|Operating profit EBITDA LSTA|Operating profit EBITDA moleculin.com (MBRX)|Galera Therapeutics, Inc. - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization MTEM (Molecular Templates Inc)